{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T17:43:05Z","timestamp":1778866985856,"version":"3.51.4"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.yebeh.2025.110578","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T08:58:20Z","timestamp":1751533100000},"page":"110578","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Seizure outcome in adult patients with valproic acid treated epilepsy: gender-related differences"],"prefix":"10.1016","volume":"173","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5415-7482","authenticated-orcid":false,"given":"Revital","family":"Gandelman-Marton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Theitler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9566","key":"10.1016\/j.yebeh.2025.110578_b0005","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0140-6736(07)60461-9","article-title":"The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"issue":"10282","key":"10.1016\/j.yebeh.2025.110578_b0010","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/S0140-6736(21)00246-4","article-title":"The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial","volume":"397","author":"Marson","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.yebeh.2025.110578_b0015","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S1474-4422(18)30107-8","article-title":"Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry","volume":"17","author":"Tomson","year":"2018","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.yebeh.2025.110578_b0020","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S1474-4422(12)70323-X","article-title":"Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study","volume":"12","author":"Meador","year":"2013","journal-title":"Lancet Neurol."},{"issue":"16","key":"10.1016\/j.yebeh.2025.110578_b0025","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1001\/jama.2013.2270","article-title":"Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism","volume":"309","author":"Christensen","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.yebeh.2025.110578_b0030","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.6606","article-title":"Association of prenatal exposure to valproate and other antiepileptic drugs with risk for attention-deficit\/hyperactivity disorder in offspring","volume":"2","author":"Christensen","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.yebeh.2025.110578_b0035","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/epi.13021","article-title":"Valproate in the treatment of epilepsy in girls and women of childbearing potential","volume":"56","author":"Tomson","year":"2015","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.yebeh.2025.110578_b0040","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/j.1600-0404.2008.01130.x","article-title":"Conversion from valproic acid onto topiramate in adolescents and adults with epilepsy","volume":"119","author":"Schreiner","year":"2009","journal-title":"Acta Neurol. Scand."},{"issue":"8","key":"10.1016\/j.yebeh.2025.110578_b0045","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1111\/epi.13437","article-title":"EURAP Study Group. Withdrawal of valproic acid treatment during pregnancy and seizure outcome: observations from EURAP","volume":"57","author":"Tomson","year":"2016","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.yebeh.2025.110578_b0050","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/epi.16407","article-title":"Doing without valproate in women of childbearing potential with idiopathic generalized epilepsy: Implications on seizure outcome","volume":"61","author":"Cerulli Irelli","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2025.110578_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.107980","article-title":"Predictors of successful valproate withdrawal in women with epilepsy","volume":"119","author":"Atalar","year":"2021","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.yebeh.2025.110578_b0060","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1212\/01.WNL.0000163771.96962.1F","article-title":"Antiepileptic drug use of women with epilepsy and congenital malformations in offspring","volume":"64","author":"Artama","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2025.110578_b0065","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1136\/jnnp.2005.074203","article-title":"Malformations risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register","volume":"77","author":"Morrow","year":"2006","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"5","key":"10.1016\/j.yebeh.2025.110578_b0070","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/j.1528-1167.2009.02129.x","volume":"50","author":"Harden","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2025.110578_b0075","unstructured":"Medicines & Healthcare Products Regulatory Agency. https:\/\/www.gov.uk\/government\/news\/safety-of-valproate-new-study-on-risks-in-children-of-men-taking-valproate. Accessed 08\/1\/2025."},{"key":"10.1016\/j.yebeh.2025.110578_b0080","unstructured":"European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/news\/precautionary-measures-address-potential-risk-neurodevelopmental-disorders-children-born-men-treated-valproate-medicines. Accessed 08\/1\/2025."},{"key":"10.1016\/j.yebeh.2025.110578_b0085","unstructured":"New Zealand Medicines and Medical Devices Safety Authority. https:\/\/www.medsafe.govt.nz\/safety\/Alerts\/Sodium_valproate_Epilim_use_in_people_who_can_father_children.asp . Accessed 08\/1\/2025."},{"key":"10.1016\/j.yebeh.2025.110578_b0090","unstructured":"Medicines & Healthcare Products Regulatory Agency. https:\/\/www.gov. uk\/government\/news\/new-valproate-safety-measures-apply-from-31-january. Accessed 08\/1\/2025."},{"issue":"1","key":"10.1016\/j.yebeh.2025.110578_b0095","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/ane.13005","article-title":"Valproate-associated foetal malformations-rates of occurrence, risks in attempted avoidance","volume":"139","author":"Vajda","year":"2019","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.yebeh.2025.110578_b0100","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.seizure.2016.11.007","article-title":"Status epilepticus in pregnant women with epilepsy after valproate adjustment: a case series","volume":"43","author":"Wu","year":"2016","journal-title":"Seizure"},{"issue":"415","key":"10.1016\/j.yebeh.2025.110578_b0105","article-title":"Valproate impact and sex-dependent seizure remission in patients with idiopathic generalized epilepsy","volume":"15","author":"Cerulli Irelli","year":"2020","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.yebeh.2025.110578_b0110","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.eplepsyres.2015.11.012","article-title":"Pharmacological outcomes in juvenile myoclonic epilepsy: support for sodium valproate","volume":"119","author":"Chowdhury","year":"2016","journal-title":"Epilepsy Res."},{"issue":"4","key":"10.1016\/j.yebeh.2025.110578_b0115","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/ane.13567","article-title":"Treatment outcomes in women with idiopathic generalized epilepsy","volume":"145","author":"Kiiski","year":"2022","journal-title":"Acta Neurol. Scand."},{"issue":"4","key":"10.1016\/j.yebeh.2025.110578_b0120","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2025.110578_b0125","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology. https:\/\/www.whocc.no\/atc_ddd_index\/. Accessed 08\/1\/2025."},{"key":"10.1016\/j.yebeh.2025.110578_b0130","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0074-7742(08)00002-0","article-title":"Epidemiology and classification of epilepsy: gender comparisons","volume":"83","author":"McHugh","year":"2008","journal-title":"Int. Rev. Neurobiol."},{"issue":"7","key":"10.1016\/j.yebeh.2025.110578_b0135","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S1474-4422(17)30114-X","article-title":"Individualised prediction model of seizure recurrence and long-term outcomes after withdrawal of antiepileptic drugs in seizure-free patients: a systematic review and individual participant data meta-analysis","volume":"16","author":"Lamberink","year":"2017","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.yebeh.2025.110578_b0140","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/epi4.12632","article-title":"Differences between men and women in response to antiseizure medication use and the likelihood of developing treatment resistant epilepsy","volume":"7","author":"Cepeda","year":"2022","journal-title":"Epilepsia Open"},{"issue":"1\u20132","key":"10.1016\/j.yebeh.2025.110578_b0145","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/jnr.23853","article-title":"Sex differences in the anticonvulsant activity of neurosteroids","volume":"95","author":"Samba","year":"2017","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.yebeh.2025.110578_b0150","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.seizure.2019.06.021","article-title":"Outcomes of low-dose valproic acid treatment in patients with juvenile myoclonic epilepsy","volume":"70","author":"G\u00fcrer","year":"2019","journal-title":"Seizure"},{"issue":"10","key":"10.1016\/j.yebeh.2025.110578_b0155","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1093\/brain\/awae128","article-title":"Morbidity and mortality risks associated with valproate withdrawal in young adults with epilepsy","volume":"147","author":"Mbizvo","year":"2024","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.yebeh.2025.110578_b0160","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1586\/ecp.10.3","article-title":"Clinical pharmacokinetic interactions between antiepileptic drugs and hormonal contraceptives","volume":"3","author":"Reddy","year":"2010","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.yebeh.2025.110578_b0165","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.seizure.2018.08.024","article-title":"Estrogen-related seizure exacerbation following hormone therapy for assisted reproduction in women with epilepsy","volume":"61","author":"Mostacci","year":"2018","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2025.110578_b0170","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1111\/j.1528-1167.2006.00629.x","article-title":"Increased apparent oral clearance of valproic acid during intake of combined contraceptive steroids in women with epilepsy","volume":"47","author":"Galimberti","year":"2006","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2025.110578_b0175","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1212\/01.WNL.0000076485.09353.7A","article-title":"Oral contraceptives reduce lamotrigine plasma levels","volume":"61","author":"Sabers","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2025.110578_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2014.05.011","article-title":"Gender issues in antiepileptic drug treatment","volume":"72","author":"Perucca","year":"2014","journal-title":"Neurobiol. Dis."},{"issue":"4","key":"10.1016\/j.yebeh.2025.110578_b0185","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1124\/pr.119.017392","article-title":"Sex differences in the epilepsies and associated comorbidities: implications for use and development of pharmacotherapies","volume":"72","author":"Christian","year":"2020","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.yebeh.2025.110578_b0190","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.seizure.2020.09.008","article-title":"Risk-benefit assessment of treatment of epileptic women of childbearing age with valproic acid","volume":"82","author":"Qu\u00edlez","year":"2020","journal-title":"Seizure"},{"issue":"Pt A","key":"10.1016\/j.yebeh.2025.110578_b0195","first-page":"1","article-title":"Why do some women with epilepsy use valproic acid despite current guidelines?","volume":"98","author":"Bosak","year":"2019","journal-title":"A single-center Cohort Study Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2025.110578_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.107706","article-title":"Response to levetiracetam or lamotrigine in subjects with Juvenile Myoclonic Epilepsy previously treated with valproic acid: a single center retrospective study","volume":"115","author":"Milano","year":"2021","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.yebeh.2025.110578_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.108449","article-title":"Impact of recommendations on sodium valproate prescription among women with epilepsy: an interrupted time-series study","volume":"125","author":"Degremont","year":"2021","journal-title":"Epilepsy Behav."},{"issue":"2","key":"10.1016\/j.yebeh.2025.110578_b0210","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S1474-4422(15)00314-2","article-title":"Valproic acid after five decades of use in epilepsy: time to reconsider the indications of a time-honoured drug","volume":"15","author":"Tomson","year":"2016","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.yebeh.2025.110578_b0215","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/j.1528-1157.1993.tb02586.x","article-title":"Incidence of Epilepsy and unprovoked seizures in Rochester Minnesota: 1935-1984","volume":"34","author":"Hauser","year":"1993","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2025.110578_b0220","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.yebeh.2018.04.009","article-title":"Changes in antiepileptic drug-prescribing patterns in pregnant women with epilepsy","volume":"84","author":"Meador","year":"2018","journal-title":"Epilepsy Behav."},{"issue":"2","key":"10.1016\/j.yebeh.2025.110578_b0225","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/ane.12965","article-title":"33. Antiepileptic drug polytherapy in pregnant women with epilepsy","volume":"138","author":"Vajda","year":"2018","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.yebeh.2025.110578_b0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2019.106165","article-title":"Clinical opinion: Earlier employment of polytherapy in sequential pharmacotherapy of epilepsy","volume":"156","author":"Lee","year":"2019","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.yebeh.2025.110578_b0235","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.seizure.2020.10.031","article-title":"Is the anticonvulsant activity of levetiracetam dose-dependent?","volume":"83","author":"Lamouret","year":"2020","journal-title":"Seizure"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152550502500318X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152550502500318X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T17:43:44Z","timestamp":1763747024000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152550502500318X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":47,"alternative-id":["S152550502500318X"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2025.110578","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Seizure outcome in adult patients with valproic acid treated epilepsy: gender-related differences","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2025.110578","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110578"}}